Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd. is an Israel-based clinical-stage oncology therapeutics company focused on developing and commercializing Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy), a localized alpha-radiation treatment for solid tumors. The company operates through subsidiaries in the United States, Japan, and Canada and develops its therapy for use in oncology centers and through commercial partners.
Business
Share of revenueLocalized alpha-radiation cancer therapy used to treat solid tumors.
Research and clinical trial activities supporting new indications and regulatory advancement.
Production and delivery of therapy components used in treatment administration.
Customers
Alpha Tau’s direct customers and counterparties are oncology treatment providers, clinical investigators, and strategic commercial partners that help bring Alpha DaRT® into clinical and commercial use. The therapy is aimed at patients with solid tumors, while hospitals and treatment centers are the users that procure, administer, or evaluate the product under clinical or partnered programs.
Buy or administer Alpha DaRT® for solid tumor treatment programs and clinical use.
Partner with Alpha Tau to commercialize the therapy, handle market access, and scale adoption.
Run investigator-initiated or company-sponsored studies to validate new indications and outcomes.
End beneficiaries of the therapy, especially in cancers where localized treatment is being studied.
Strategy
Alpha Tau’s strategy is to expand Alpha DaRT® from a single-asset clinical story into a multi-indication oncology platform with both trial execution and commercialization pathways. The company is prioritizing partnership-led market entry, broader clinical validation across tumor types, and manufacturing readiness to support future adoption.
Broader data can support regulatory progress and adoption in more oncology settings.
Partners can provide sales execution, market access, and reimbursement expertise.
Commercial rollout requires reliable production and distribution of treatment components.
Geography
Alpha Tau is headquartered in Israel and has built an operating footprint that includes the United States, Japan, and Canada through wholly owned subsidiaries. The business is geographically important because clinical development is conducted across multiple markets, while commercialization is expected to depend heavily on the U.S. and other major oncology markets.
Risks
Alpha Tau faces the execution risk typical of clinical-stage oncology companies: clinical trials may fail to confirm efficacy or safety, delaying regulatory and commercial progress. The business also depends on partner execution, manufacturing readiness, and funding support, while oncology adoption can be slow because hospitals must justify new treatment workflows and evidence standards.
- Clinical development failureImpact: HighLikelihood: Medium
The value of Alpha DaRT® depends on positive safety and efficacy data across indications.
Exposure: Multiple solid-tumor programs and pivotal trials
- Commercial partner dependenceImpact: HighLikelihood: Medium
U.S. commercialization and customer engagement may rely on third-party execution.
Exposure: Tolmar collaboration and similar future partnerships
- Capital-intensive development cycleImpact: HighLikelihood: Medium
Long clinical timelines and commercialization buildout require sustained funding.
Exposure: Clinical-stage oncology platform
- Manufacturing and supply chain executionImpact: MediumLikelihood: Medium
The company must produce and deliver treatment components consistently to support trials and sales.
Exposure: Alpha DaRT® manufacturing and supply
Accounting
Judgemental itemsClinical trial and development costs are expensed as incurred, driving volatility in reported results.
Impact: Affects operating loss and comparability across periods
Equity awards to employees and directors are a significant non-cash expense in biotech companies.
Impact: Affects net loss and diluted share count
Operating lease right-of-use assets and liabilities reflect facility commitments and occupancy costs.
Impact: Affects balance sheet leverage and operating expense presentation
Management must estimate accruals and other judgments that can affect reported liabilities and expenses.
Impact: Affects consistency of reported results
Similar listed companies
Publicly listed companies with a comparable business focus.
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Lantern Pharma Inc.
LTRN · Pharmaceutical Preparations
Alvotech
ALVO · Biological Products, (No Diagnostic Substances)
Alvotech is a U.S.-listed biotechnology company focused on developing and manufacturing biosimilar medicines.
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026